Deals Shaping The Medical Industry, April 2015
Executive Summary
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced March 2015.
You may also be interested in...
First Test That Predicts Severe Outcomes In COVID-19 Patients Receives CE Mark
MeMed’s test measures immune system response to assess a patient’s COVID-19 trajectory.
Industry Ready To Embrace Digitalization, Says IGBA
IGBA chair Sudarshan Jain has indicated that “companies are undergoing the change towards digital health,” in the second part of an exclusive interview with Generics Bulletin in which Jain and IGBA secretary general Suzette Kox talk about the pandemic-driven shift towards digitalization and computerization.
Jubilant To Reorganize With Generics API Business On The Move
Jubilant Pharmova – formerly Jubilant Life Sciences – plans to separate and move the active pharmaceutical ingredient business currently in the hands of its generic pharmaceuticals subsidiary, taking eventual control of the business itself.